Brokerages Set Cidara Therapeutics Inc (CDTX) Price Target at $9.75

Cidara Therapeutics Inc (NASDAQ:CDTX) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.25.

Several research firms recently issued reports on CDTX. Zacks Investment Research upgraded Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Wednesday. Wedbush lowered Cidara Therapeutics from an “outperform” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Friday, May 17th. ValuEngine lowered Cidara Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $15.00 target price on shares of Cidara Therapeutics in a report on Monday, April 15th.

CDTX opened at $1.92 on Tuesday. Cidara Therapeutics has a 52-week low of $1.85 and a 52-week high of $6.35. The stock has a market cap of $51.15 million, a P/E ratio of -0.83 and a beta of 2.13. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.19 and a current ratio of 3.19.



Cidara Therapeutics (NASDAQ:CDTX) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). Equities research analysts predict that Cidara Therapeutics will post -1.69 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDTX. Renaissance Technologies LLC increased its position in Cidara Therapeutics by 8.6% during the third quarter. Renaissance Technologies LLC now owns 309,700 shares of the biotechnology company’s stock worth $1,363,000 after buying an additional 24,400 shares during the last quarter. Vanguard Group Inc. increased its position in Cidara Therapeutics by 15.0% during the third quarter. Vanguard Group Inc. now owns 660,485 shares of the biotechnology company’s stock worth $2,906,000 after buying an additional 85,979 shares during the last quarter. Vanguard Group Inc increased its position in Cidara Therapeutics by 15.0% during the third quarter. Vanguard Group Inc now owns 660,485 shares of the biotechnology company’s stock worth $2,906,000 after buying an additional 85,979 shares during the last quarter. Alethea Capital Management LLC increased its position in Cidara Therapeutics by 10.3% during the fourth quarter. Alethea Capital Management LLC now owns 482,357 shares of the biotechnology company’s stock worth $1,134,000 after buying an additional 45,000 shares during the last quarter. Finally, Trellus Management Company LLC increased its position in Cidara Therapeutics by 105.8% during the fourth quarter. Trellus Management Company LLC now owns 94,143 shares of the biotechnology company’s stock worth $221,000 after buying an additional 48,391 shares during the last quarter. Institutional investors and hedge funds own 65.97% of the company’s stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.

Recommended Story: Overbought

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.